Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Vical Incorporated Reports Third Quarter 2014 Financial Results And Progress In Key Development Programs

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and nine months ended September 30, 2014. The net loss for the third quarter of 2014 was $4.4 million, or $0.05 per share, compared with a net loss of $9.9 million, or…

North County Medical Group Aims to Raise the 64%

October 30, 2014 – 5:00 am | Edit Post

VISTA, CA–(Marketwired – Oct 30, 2014) – In 2012 the Affordable Care Act determined that women over 40 are entitled to breast cancer mammography screenings every 1 to 2 years. So why is the national average for mammogram screenings for eligible individuals at only 64%? A local North County San Diego medical group is taking this question personally. After all, the best defense again breast cancer is early detection.

Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial For SD-809 In Tardive Dyskinesia

October 30, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the enrollment of the first patient in a multi-center Phase…

Enzyme could help explain life’s origin

October 29, 2014 – 10:20 pm | Edit Post

Enzyme made by Scripps Research scientists could lead to new class of therapies.

EEG Test to Help Understand and Treat Schizophrenia

October 29, 2014 – 8:53 am | Edit Post

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.

EEG Test to Help Understand and Treat Schizophrenia

October 29, 2014 – 8:53 am | Edit Post

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.

EEG Test to Help Understand and Treat Schizophrenia

October 29, 2014 – 8:53 am | Edit Post

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.

Innovation in Ireland: Overview to Xconomy’s Special Report

October 29, 2014 – 6:05 am | Edit Post

Until earlier this October, the only time I had visited Ireland was in April of 1989, on the World B. Tour. A group of American former collegiate basketball players came to the Emerald Isle on a…

[[Click headline to continue reading.]]

Sanford-Burnham welcomes two new scientists to Lake Nona

October 29, 2014 – 6:00 am | Edit Post

We’re excited to announce that we have recruited two cardiometabolic experts to our Medical City campus in Lake Nona (Orlando), Fla. Peter A. Crawford, M.D., Ph.D., and Andre d’Avignon, Ph.D., join our Cardiovascular Pathobiology Program from Washington University in St. Louis, Mo.

ViaCyte’s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient

October 29, 2014 – 6:00 am | Edit Post

SAN DIEGO, Oct. 29, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the first patient in its Phase 1/2 study was successfully implanted with VC-01™, its embryonic stem cell-derived islet replacement product candidate being developed as a treatment for type 1 diabetes.  This Phase 1/2 clinical trial, designed to evaluate the VC-01 product candidate directly in patients with type 1 diabetes, is initially being conducted at UC San Diego Health System, with the support of the UC San Diego Sanford Stem Cell Clinical Center, under the direction of Principal Investigator Robert Henry, MD.  

Dr. Paul Laikind, President and CEO of ViaCyte, said, “We are very excited to begin the clinical stage of development in our quest to transform the way patients with type 1 diabetes are impacted by the disease.  To our knowledge, this is the first time that an embryonic stem cell-derived cell replacement therapy for diabetes has been studied in human subjects, and it represents the culmination of a decade of effort by the ViaCyte team, our collaborators, and our supporters at the California Institute for Regenerative Medicine and at JDRF.” 

The loss or malfunction of insulin-producing beta cells is the primary cause of type 1 diabetes, making it a promising target disease for cell replacement therapy.  ViaCyte’s VC-01 product candidate delivers pancreatic precursor cells (called PEC-01™ cells) that are designed to further differentiate and mature after surgical implantation, not only to fully functioning insulin-producing beta cells, but also to other endocrine cell types that make up the normal human pancreatic islet.  Thus, along with the critically important insulin, the implanted cells are expected to produce other hormones that are important for the regulation of glucose (sugar) in the blood, including, for example, glucagon, somatostatin, and amylin. 

The PEC-01 cells are delivered under the skin in a proprietary device with a selectively porous cell-impermeable membrane, called the Encaptra® drug delivery system.  The Encaptra device is designed to protect the implanted cells from possible immune rejection, to permanently contain the cells and prevent their distribution away from the implantation site, and to provide a platform for product vascularization. 

The ongoing Phase 1/2 clinical trial is evaluating the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  In addition to determining the safety of the product candidate in these patients, the study is designed to evaluate the effectiveness of the VC-01 product candidate in replacing the lost endocrine function that is central to the disease.  In an open-label, dose-escalating format, ViaCyte expects to enroll approximately 40 patients in the study at multiple clinical sites. 

About Type 1 Diabetes Type 1 diabetes mellitus (previously called juvenile diabetes) is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy.  It is typically diagnosed during childhood or adolescence, though it can also arise in adults.  Though less common than type 2 diabetes, which occurs when the body becomes resistant to insulin, type 1 diabetes affects several million Americans, according to JDRF, the leading global organization focused on type 1 diabetes research.  Currently, there is no cure for type 1 diabetes and the risk of long-term complications is high even with diligent treatment.  Standard treatment involves multiple daily injections of insulin and rigorous management of diet and lifestyle. 

About ViaCyte  ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte’s lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  VC-01 is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine and JDRF. For more information, please visit www.viacyte.com.

About Sanford Stem Cell Clinical Center at UCSD  The Sanford Stem Cell Clinical Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapies. 

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte, Inc.